Oncology News | pharmaphorum

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

News

Study finds hundreds of overlooked cancer drug targets

Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be use

News

FDA starts review of Lantheus’ generic Lutathera

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tu

DISCO dances out of the shadows with €20m for ‘surfaceome’

Roche bags EU okay for subcutaneous Tecentriq

Update: Orion buys stake in LegoChem as biotech push goes on

Keytruda breaks new ground in cervical cancer

Study finds hundreds of overlooked cancer drug targets

FDA starts review of Lantheus’ generic Lutathera

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks